510(k) Report

510(k) · Cleared

Cleared

Core Metabolic

K251157510(k) TraditionalCleared Jan 9, 2026269-day reviewClass II21 CFR 862.1035

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Truvian Health · CIX Bromcresol Green Dye-Binding, Albumin

Cleared on Jan 9, 2026 as substantially equivalent to K200898 (Medicon Hellas S.A, 2021) and 1 other predicate after a 269-day review. Its family tree reaches back 2 generations to 1992.

Decided
Jan 9, 2026
Review
269 days
Class
Class II
Product code
CIX
Recalls
None
Predicates
2

Its longest line of descent runs back 2 generations to K924964 (1992). 9 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 2 generations backK924964 Olympus Total Bilirubin ReagentOlympus Corp. · 1992
  2. 1 generation backK200898 Medicon Hellas Albumin, Medicon Hellas Calcium, Medicon Hellas…Medicon Hellas S.A · 2021
  3. This deviceK251157 Core MetabolicTruvian Health · 2026
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K924964Olympus Total Bilirubin ReagentOlympus Corp.1992—
−1K200898Medicon Hellas Albumin, Medicon Hellas Calcium, Medicon Hellas Creatinine…Medicon Hellas S.A2021—
0 (this device)K251157Core MetabolicTruvian Health2026—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199320
199530
200210
200610
FIG. 1 — Lineage of K251157, 1992–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in CIX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new CIX device

  1. #1 K200898 Medicon Hellas Albumin, Medicon Hellas…score 5.0 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K200898Medicon Hellas Albumin, Medicon Hellas Calcium, Medicon Hellas Creatinine, Medicon…
Summary page 6
…1 Hellas Direct Bilirubin and Medicon Hellas Urea Nitrogen (K200898) Secondary Predicate Device: Abaxis Piccolo Primary Health Panel (K950164) 4 Device Description The TruSy…
Medicon Hellas S.A2021—
*K950164Piccolo (TM) Primary Health Panel Reagent Rotor
Summary page 6
…Medicon Hellas Urea Nitrogen (K200898) Secondary Predicate Device: Abaxis Piccolo Primary Health Panel (K950164) 4 Device Description The TruSystem is an automated, integrated in vitro diagnostic platform consisting of the TruVerus™ and…
Abaxis, Inc.19951

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 34 years and passes through 3 companies; a new generation was cleared every 28.8 years on median.
  • 2 of the 9 ancestors have a recall of any class.

How does its category compare?

All CIX devices

CIX Bromcresol Green Dye-Binding, Albumin: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.

FDA decisions per year · CIX

2in 2021

2007: 12008: 12009: 12011: 32012: 12013: 12018: 12019: 12021: 22026 (partial year): 1
2007high 3 (2011) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CIX

168in 2011

2011: 168 days median
2007high 168 (2011)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · CIX

1in 2020

2008: 12010: 12013: 12019: 12020: 1
2007high 1 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · CIX

4in 2025

2007: 12010: 742011: 82012: 22016: 12017: 62018: 22020: 12021: 32022: 12023: 42024: 32025: 4
2007high 74 (2010) · low 0 (2008)2025

MAUDE reports naming product code CIX, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—01
20081—10
20091—00
20100—174
2011316808
20121—02
20131—10
20140—00
20150—00
20160—01
20170—06
20181—02
20191—10
20200—11
20212—03
20220—01
20230—04
20240—03
20250—04
20261—0—

What is it indicated for?

The Core Metabolic panel is part of the TruWellness Panel™ and is intended for use on the TruVerus™. The Core Metabolic panel (part of the TruWellness Panel™) is an in vitro diagnostic device and intended to be used for the quantitative determination of Glucose (GLU), Total Protein (TP), and Albumin (ALB) in lithium-heparinized venous whole blood in clinical laboratory or point-of-care settings. The Core Metabolic panel (part of the TruWellness Panel™)…

Read the full statement (150 words)

The Core Metabolic panel is part of the TruWellness Panel™ and is intended for use on the TruVerus™. The Core Metabolic panel (part of the TruWellness Panel™) is an in vitro diagnostic device and intended to be used for the quantitative determination of Glucose (GLU), Total Protein (TP), and Albumin (ALB) in lithium-heparinized venous whole blood in clinical laboratory or point-of-care settings.

The Core Metabolic panel (part of the TruWellness Panel™) is an in vitro diagnostic test system that aids the physician in the diagnosis and treatment of the following disorders in adults 18 years of age or older:

- Glucose (GLU): Carbohydrate metabolism disorders, including diabetes mellitus, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

- Total Protein (TP): Variety of diseases involving the liver, kidney, or bone marrow, as well as other metabolic and nutritional disorders.

- Albumin (ALB): Numerous diseases involving primarily the liver and kidneys.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K251157: Core Metabolic.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K251157

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026